Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A; UroScreen Study Group.
Huber S, et al. Among authors: gawrych k.
BJU Int. 2012 Sep;110(5):699-708. doi: 10.1111/j.1464-410X.2011.10883.x. Epub 2012 Feb 7.
BJU Int. 2012.
PMID: 22313585